REFERENCES

1. Bondy B, Buettner A, Zill P. Genetics of suicide. Mol Psychiatry 2006;11:336-51.

2. Lu DY. Suicide risks and treatments, new ideas and future perspectives. New York, US: Nova Science Publishers; 2017.

3. Serafini G, Salano P, Amore M. Suicidal ideation: a comprehensive overview. Bradley Weaver. US: Nova Science Publishing; 2015. pp. 1-42.

4. Lu DY, Lu TR, Lu Y, Cao S. Introduction for suicide study. J Metab Syndr 2017;6:227.

5. Lu DY, Lu TR, Zhu PP, Che JY. The efficacies and toxicities of antidepressant drugs in clinics, building the relationship between Chemo-Genetics and Socio-Environments. Cent Nerv Syst Agents Med Chem 2016;16:12-8.

6. Marreros A. Mood disorders: epidemiology and natural history. Psychiatry 2008;8:52-5.

7. Lu DY, Zhu PP, Wu HY, Yarla NS, Zhu H, et al. Human suicide study, is there an association between suicide and mental illness. Metabolomics 2016;6:186.

8. Davison K. Historical aspects of mood disorders. Psychiatry 2006;5:115-8.

9. Lu DY, Wu HY, Cao S, Lu Y, Yarla NS, et al. Historical analysis of suicide/mental disorder and current diagnostics in clinics. Suicide Risks and Treatments, New Ideas and Future Perspectives. New York, US: Nova Science Publishers; 2017. pp. 1-12.

10. Shandilya S. Suicide and suicide prevention: a historical review. Res J Social Sci 2018;9:35-40.

11. Azuero AJ, Arreaza-kaufman D, Caria J, Tasinari S, Faria A, et al. Suicide in the indigenous population of Latin America: a systematic review. Availabel from: http://dx.doi.org/10.1016/j.rcp.2016.12.002. [Last accessed on 4 Jun 2020].

12. Fountoulakis KN. Suicide rate in Greece stabilizes at historically high levels but still lowest in Europe. J Affect Disord 2019;254:117-9.

13. Dhungel B, Sugai MK, Gilmour S. Trends in suicide mortality by methods from 1979 to 2016 in Japan. Int J Environmental Res Public Health 2019;16:1794.

14. Kino S, Jang SN, Gero K, Kato S, Kawachi I. Age, period, cohort, trends of suicide in Japan and Korea (1986-2015): a tale of two countries. Soc Sci Med 2019;235:112385.

15. McNicolas F. Suicide in Europe: an on-going public health concern. Soc Psihijat 2017;45:22-9.

16. Snowdon J, Phillips J, Zhong BL, Yamauchi T, Chiu HFK, et al. Changes in age patterns of suicide in Australia, the United States, Japan and Hong Kong. J Affect Disord 2017;211:12-9.

17. Steelesmith D, Fontanella CA, Campo JV, Bridge JA, Warren KL, et al. Contextural factors associated with county-level suicide rates in the United States, 1999 to 2016. JAMA 2019;2:e1910936.

18. Lu DY, Lu TR, Zhu PP, Che JY. Genetics and bioinformatics study of antidepressant drugs, recent advancements and future trends. Bradley Weaver. US: Nova Science Publishing; 2015. pp. 57-71.

19. While D, Bickley H, Roscoe A, Windfuhr K, Rahman S, et al. Implementation of mental health service recommendations in England and Wales and suicide rates, 1997-2006: a cross-sectional and before-and-after observational study. Lancet 2012;379:1005-12.

20. Frangou S. Brain structural changes in mood disorders. Psychiatry 2009;8:105-6.

21. Roiser JP, Rubinsztein JS, Sahakian BJ. Neuropsychology of affective disorders. Psychiatry 2009;8:91-6.

22. Frangou S. Functional neuroimaging in mood disorder. Psychiatry 2008;6:102-4.

23. Desmyter S, Bijttebier S, Heeringen KV. The role of neuroimaging in our understanding of the suicidal brain. CNS Neurol Disord Drug Targets 2013;12:921-9.

24. Lu DY, Lu TR, Yarla NS, Wu HY. Genetics in suicide treatments, modern diagnosis establishments. J Mental Disord Treat 2017;3:145.

25. Kendell R. Diagnosis and classification of mood disorders. Psychiatry 2006;5:112-4.

26. Lu DY, Lu TR, Che JY, Zhu PP. Genetics and bioinformatics studies of antidepressant drug therapeutic efficacies and toxicities, a current overview. Recent Pat CNS Drug Discov 2014;9:193-9.

27. McAllister-Williams R, Ferrier IN. Pharmacological management of unipolar affective disorder. Psychiatry 2009;8:113-9.

28. McAllister-Williams R, Ferrier IN. Pharmacological management of bipolar affective disorder. Psychiatry 2009;8:120-4.

29. Lucas G. Fast-acting antidepressants: are we nearly there. Expert Rev Neurotherapeutics 2008;8:1-3.

30. Menchetti M, Bortolotti B, Rucci P, Scocco P, Bombi A, et al. Depression in primary care: Interpersonal counseling vs selective serotonin reuptake inhibitors. The DEPICS study. A multicenter randomized controlled trial. Rationale and design. BMC Psychiatry 2010;10:97.

31. Menchetti M, Rucci P, Bortolotti B, Bombi A, Scocco P, et al. Moderators of remission with interpersonal counseling or drug treatment in primary care patients with depression: randomized controlled trial. Br J Psychiatry 2014;204:144-50.

32. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 2012;148:1223-41.

33. Krystal JH, State MW. Psychiatric disorders: diagnosis to therapy. Cell 2014;157:201-14.

34. Desmyter S, Bijttebier S, Heeringen KV. The role of neuroimaging in our understanding of the suicidal brain. CNS Neurol Disord Drug Targets 2013;12:921-9.

35. Lu DY, Zhu PP, Wu HY, Yarla NS, Xu B, et al. Human suicide risk and treatment study. Cent Nerv Syst Agents Med Chem 2018;18:206-12.

36. Lu DY, Che JY, Wu HY, Lu TR, Putta S. Suicide risks and prevention, neuropathogenic study. Edeweiss Psyi Open 2020;4:124.

37. Eagles JM. Light therapy and seasonal affective disorder. Psychiatry 2009;8:125-9.

38. Cao S, Lu DY, Lu TR, Yarla NS. Future directions in the field of suicide study. EC Orthopaedics 2017;6:206-8.

39. Lu DY, Lu TR, Zhu PP. Undesired neural side-effects of a drug, a chemical and genetic interrelated problem. Cent Nerv System Agent Med Chem 2010;10:108-12.

40. Lu DY, Yarla NS, Lu TR, Varki A, Xu B, et al. Pathology and medication for human suicide. Cell Dev Biol 2019;8:201.

41. Lu DY, Zhu PP, Lu TR, Che JY. The suicidal risks and treatments, seek medications from multi-disciplinary. Cent Nerv Syst Agents Med Chem 2016;16:231-9.